The offer was made in connection with Abbott’s acquisition of Alere, which closed yesterday.
A total of 1.7 million shares of preferred stock were tendered in the offer, representing 98.5% of the outstanding shares of preferred stock, Abbott said in a press release.
All conditions in the offering have been satisfied, and Abbott said that payment of the offer price for shares of preferred stock will be “promptly made by the depositary.”
The offer was originally slated to expire at midnight on August 11, and was previously extended to August 31.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.